Corvallis Clinic Clinical Research Center Active Study List 6/4/2024 Page 1 of 1					
Indication	Sponsor Protocol Number NCT Number	Study Description	Investigator 24 Hour Contact Info	Study Coordinator Regular Business Hours Contact Info (Primary Coord. Listed First)	Sponsor Emergency Contact If local contacts are unavailable
Type 2 Diabetes	Eli Lilly J1I-MC-GZBZ NCT06260722 *Enrolling	A Phase 3, Randomized, Multicenter, Openlabel Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly Compared with Semaglutide Once Weekly in Adult Participants with Type 2 Diabetes and Inadequate Glycemic Control with Metformin with or without SGLT2 Inhibitor (TRANSCEND-T2D-2)	Brian Curtis, MD	Erin Thompson Kim Tally	463-221-7267 Carolina Casellini
Type 2 Diabetes	Eli Lilly J2A-MC-GZGU NCT06045221 * In follow up	A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Once Daily Oral LY3502970 Compared with Oral Semaglutide in Adult Participants with Type 2 Diabetes and Inadequate Glycemic Control with Metformin (ACHIEVE-3)	Shannon Hopson, DO Beth Rathbun, PA-C 541-754-1150	Rich Tomasco Erin Thompson 541-766-2163	765-418-0528
Type 2 Diabetes	Eli Lilly J2A-MC-GZGT NCT05971940 *In follow up	A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once Daily Oral LY3502970 Compared with Placebo in Adult Participants with Type 2 Diabetes and Inadequate Glycemic Control with Diet and Exercise Alone (ACHIEVE-1)	Shannon Hopson, DO Beth Rathbun, PA-C 541-754-1150	Erin Thompson Josh Borunda 541-766-2163	317-997-5593
Type 2 Diabetes	Eli Lilly I8F-MC-GPHE NCT05433584 *In follow up	A Randomized, Open-Label, Parallel-Group, Two-Arm, Phase 4 Study to Evaluate the Long-Term Efficacy and Safety of Tirzepatide Compared with Intensified Conventional Care in Adults When Initiating Treatment Early in the Course of Type 2 Diabetes (SURPASS-EARLY)	Brian Curtis, MD 541-754-1150	Rich Tomasco Josh Borunda 541-766-2163	317-651-8478
Metabolic Outcomes in obese patients with cardiovascular disease (or risk of)	Eli Lilly SURMOUNT-MMO I8F-MC-GPIJ NCT05556512 *In follow up	Study to Investigate the Effect of Tirzepatide on the Reduction of Morbidity and Mortality in Adults with Obesity	Brian Curtis, MD 541-754-1150	Kim Tally Josh Borunda 541-766-2163	+34 91 6233535